Management of pharmacovigilance during the COVID‐19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial

• Váldodahkkit: Noémie Mercier (Dahkki), Drifa Belhadi (Dahkki), Aline DeChanet (Dahkki), Christelle Delmas (Dahkki), Juliette Saillard (Dahkki), Marina Dumousseaux (Dahkki), Soizic Le Mestre (Dahkki), Claire Fougerou‐Leurent (Dahkki), Assia Ferrane (Dahkki), Charles Burdet (Dahkki), Hélène Espérou (Dahkki), Florence Ader (Dahkki), Maya Hites (Dahkki), Nathan Peiffer‐Smadja (Dahkki), Julien Poissy (Dahkki), Claire Andrejak (Dahkki), José Artur Paiva (Dahkki), Evelina Tacconelli (Dahkki), Thérèse Staub (Dahkki), Richard Greil (Dahkki), Dominique Costagliola (Dahkki), France Mentre (Dahkki), Yazdan Yazdanpanah (Dahkki), Alpha Diallo (Dahkki), the DisCoVeRy Safety Working group (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2023-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract The current COVID‐19 pandemic was an exceptional health situation, including for drug use. As there was no known effective drug for COVID‐19 at the beginning of the pandemic, different drug candidates were proposed. In this article, we present the challenges for an academic Safety Departmen...